<DOC>
	<DOCNO>NCT02679729</DOCNO>
	<brief_summary>This Phase 1 , first-in-human ( FIH ) single ascend dose study conduct good understand safety , tolerability pharmacokinetics AZD5634 healthy subject</brief_summary>
	<brief_title>To Assess Safety , Tolerability Pharmacokinetics AZD5634 Following Inhaled Intravenous ( IV ) Dose Administration</brief_title>
	<detailed_description>This study Phase I , FIH , randomize , single-blinded ( study center staff remain blinded dosing phase study ) , placebo-controlled , single ascend dose , sequential dose group study healthy male subject and/or female subject non-childbearing potential single study center ass AZD5634 follow inhaled intravenous dose administration</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male and/or female subject age 18 50 year suitable vein cannulation repeat venipuncture . 3 . Females must negative pregnancy test screen admission unit , must lactate must nonchildbearing potential , confirm screen fulfil 1 follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment folliclestimulating hormone ( FSH ) level postmenopausal range . Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy , tubal ligation . 4 . Have body mass index ( BMI ) 18 30 kg/m2 , inclusive , weigh least 50 kg 100 kg , inclusive . 5 . Have FEV1 ( Forced expiratory volume 1 second liter ) ≥ 80 % predict value screening . 6 . Provision sign , write date informed consent optional genetic/biomarker research . 1 . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week administration investigational medicinal product ( IMP ) . 4 . Any clinically significant abnormality clinical chemistry , hematology , urinalysis result , judged investigator . 5 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) . 6 . Abnormal vital sign , 10 minute supine rest , screen checkin , define follow : Systolic blood pressure ( SBP ) &lt; 90mmHg ( millimeter mercury ) ≥ 140 mmHg Diastolic blood pressure ( DBP ) &lt; 50mmHg ≥ 90 mmHg Heart Rate &lt; 45 &gt; 85 beat per minute ( bpm ) 7 . Any clinically significant abnormality rhythm , conduction morphology rest electrocardiogram ( ECG ) clinically significant abnormality 12lead ECG , consider investigator may interfere interpretation QTc ( QT [ ECG interval measure onset QRS complex end T wave ] interval correct heart rate ) interval change , include abnormal STTwave morphology , particularly protocol define primary lead leave ventricular hypertrophy , screen . 8 . PR ( PQ [ ECG interval measure onset P wave onset QRS complex ] ) interval prolongation ( &gt; 240 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree atrioventricular ( AV ) block , AV dissociation , screen . 9 . Persistent intermittent complete bundle branch block ( BBB ) , incomplete bundle branch block ( IBBB ) , intraventricular conduction delay ( IVCD ) QRS &gt; 110 m . Subjects QRS ( ECG interval measure onset QRS complex J point ) &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation , screen . 10 . Serum/plasma potassium level outside normal range lower 3.5 5.1 mEq/L ( milliequivalent per liter ) screen prior dosing . 11 . Has active lung disease/asthma require treatment . 12 . Known suspected history drug abuse , judge investigator . 13 . Current smoker smoke used nicotine product within previous 3 month . 14 . History alcohol abuse excessive intake alcohol , judge investigator . 15 . Positive screen drug abuse , cotinine ( nicotine ) , alcohol screen admission unit . 16 . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD5634 . 17 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge investigator . 18 . Use drug enzyme induce property St John 's Wort within 3 week prior administration IMP . 19 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior administration IMP long medication long halflife . 20 . Plasma donation within 1 month screen blood donation/blood loss &gt; 500 mL 3 month prior screen . 21 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month administration IMP study . The period exclusion 3 month final dose previous study . Note : Subjects consent screen , randomize study previous phase I study , exclude . 22 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . 23 . Involvement Astra Zeneca , PAREXEL study site employee close relative . 24 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 25 . Subjects vegans medical dietary restriction . 26 . Subjects communicate reliably investigator . In addition , follow regarded criterion exclusion genetic research : 27 . Previous bone marrow transplant . 28 . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>inhale dose</keyword>
	<keyword>intravenous dose</keyword>
	<keyword>healthy subject</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AZD5634</keyword>
	<keyword>jet nebulizer</keyword>
</DOC>